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Abstract 
 
One of the main goals in Nanomedicine is to create innovative drug delivery systems 
(DDS) capable of delivering drugs into a specific location with high efficiency. In the 
development of DDS, some essential properties are desired, such as biocompatibility and 
biodegradability. Furthermore, an ideal DDS should be able to deliver a drug in a controlled 
manner and minimize its side effects. These two objectives are still a challenge for researchers 
all around the world. 
Nanogels are an excellent vehicle to use in drug delivery and several other applications 
due to their biocompatibility. They are polymer-based networks, chemically or physically 
crosslinked, with at least 80-90% water in their composition. Their properties can be tuned, 
like the nanogel size, multifunctionality and degradability. Nanogels are capable of carrying 
in their interior bioactive molecules and deliver them into cells. 
The main objective of this project was to produce nanogels for the delivery of 
anticancer drugs with the ability of responding to existent stimuli inside cells (cell-
responsiveness nanogels) and/or of controlled drug delivery. The nanogels were mainly based 
on alginate (AG), a natural biopolymer, and prepared using emulsion approaches. After their 
synthesis, they were used to encapsulate doxorubicin (Dox) which was chosen as a model 
drug. In the first part of the experimental work, disulfide-linked AG nanogels were prepared 
and, as expected, were redox-sensitive to a reducing environment like the intracellular 
medium. In the second part, AG nanogels crosslinked with both calcium ions and cationic 
poly(amidoamine) dendrimers were developed with improved sustained drug delivery. The 
prepared nanogels were characterized in terms of size, chemical composition, morphology, 
and drug delivery behavior (under redox/pH stimuli). The in vitro cytotoxicity of the nanogels 
was also tested against CAL-72 cells (an osteosarcoma cell line).  
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Resumo 
 
Um dos principais objetivos da Nanomedicina é criar um sistema inovador de entrega 
de fármacos, capaz de entregar com elevada eficácia os fármacos em locais específicos. No 
desenvolvimento destes, são desejáveis propriedades como a biocompatibilidade e a 
biodegradabilidade. Um sistema de entrega de fármacos ideal é capaz de entregar o fármaco 
e minimizar os efeitos secundários a ele associados. Estes dois objetivos continuam a 
representar um desafio para os investigadores de todo o mundo. 
Os nanogéis são constituídos por redes à base de polímeros reticulados química ou 
fisicamente, com pelo menos 80-90% de água na sua composição. São um excelente veículo 
para uso na entrega de fármacos e em várias outras aplicações por apresentarem excelente 
biocompatibilidade. Devido à sua estrutura, os nanogéis podem transportar no seu interior 
moléculas ativas e entregá-las nas células. As suas propriedades podem ser controladas, tais 
como o tamanho, a multifuncionalidade e a degradabilidade. 
O principal objetivo deste projeto foi criar nanogéis para a entrega de fármacos 
anticancerígenos com a capacidade de responder a estímulos presentes no interior das células 
e/ou de libertar o fármaco de forma controlada. Os nanogéis foram constituídos à base de 
alginato (AG), um biopolímero natural, e sintetizados utilizando métodos de emulsão. Após 
a sua síntese, os nanogéis foram usados no encapsulamento de doxorrubicina (Dox), 
escolhida como fármaco modelo. Na primeira parte do trabalho experimental, foram 
preparados nanogéis de AG reticulados através de pontes dissulfureto e capazes de responder 
a ambientes redutores como aqueles existentes no interior das células. Na segunda parte, 
desenvolveram-se nanogéis de AG reticulados por ligações estabelecidas por iões cálcio e 
dendrímeros catiónicos de poli(amidoamina) com uma capacidade melhorada de entregar o 
fármaco de forma controlada. Estes nanogéis foram caracterizados em termos de dimensão, 
composição química, morfologia e comportamento de libertação do fármaco (sob estímulos 
do tipo redox/pH). A citotoxicidade dos nanogéis foi também testada usando células CAL-
72 (uma linha de células de osteossarcoma). 
 
 
Palavras-chave: entrega de fármacos, nanogéis, responsividade celular, alginato, 
anticancerígeno 
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3 
1. GENERAL INTRODUCTION 
 
1.1. Drug Delivery Systems 
 
Nowadays, nanoscience and nanotechnology are getting a huge attention due to the 
advances that they are bringing to different scientific areas. The biomedical field, for example, 
is one with increasing research developments and with real applications in diagnosis, 
prevention and treatment of several diseases(1, 2). Other applications include tissue 
engineering, biomedical implants and bionanotechnology(3). 
Nanomedicine strongly relies on drug delivery systems (DDS) at the nanoscale which 
shows unique physical, chemical and biological properties(1). DDS are being developed to 
target and treat specific areas in the body taking advantage of complex formulations and drug 
delivery controlled release(4). The DDS can also be designed having in mind the type of 
administration route which can be oral, intravenous, arterial, transdermal, suppository, nasal, 
subcutaneous, sublingual, amongst others(5). Issues related to low aqueous solubility of some 
drugs, drug degradation by the biological system leading to lower drug efficiency and 
undesirable drug accumulation in organs or tissues are unwanted effects that nanoscience 
need to control(5). In anticancer therapy, for example, the DDS are often administrated 
directly intravenously and it is important that the drug diffuses from the bloodstream to the 
exact location, more specific/precisely to the tumor cells(6).  
To accomplish the nanomedicine objectives, one should consider some factors when 
designing DDS, like the chemical and physical properties of the drug, the route of 
administration, the nature of the delivery vehicle, the drug release mechanism, the potential 
for cell/tissue targeting and, above all, the biodegradability and biocompatibility of the 
system(4, 7, 8). All these factors have a huge impact when designing an ideal DDS, but are not 
easy to be taken in mind in a single system.  
The main goal to develop DDS is to improve the bioavailability and pharmacokinetics 
of the therapeutic agents, with systems capable of passing through the biological barriers and 
deliver the drugs into a specific location(1, 9, 10). However, DDS still present some problems 
that need to be overcome, like poor intracellular delivery, lack of control over the release 
behavior and difficulty in targeting the diseased cells/tissues which can lead to important side 
effects (the DDS, themselves, can show some toxicity)(11). In summary, DDS should: present 
a high loading capacity; maintain an optimal therapeutic drug concentration in the blood; 
show a sustained drug delivery with predictable and reproducible release rates with no early 
drug release; enhance the activity duration of short half-life drugs; target specific cells and 
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tissues; conduct to reduced side effects by being made of biocompatible/biodegradable 
materials; and allow patient compliance and optimized therapy(4, 5, 12). One important fact is 
that these systems can even modulate and change the biodistribution profile of the drugs 
depending on the different methods of administration(1). Furthermore, with the use of an ideal 
DDS, just a minor amount of drug will be required to obtain a therapeutic effect and a 
decrease on the side effects(13). 
 
 
1.2. Drug delivery systems based on polymers 
 
The DDS used in nanomedicine include viral vectors, polymer-based vehicles (e.g. 
dendrimers, peptides and polymersomes), lipid based nanosystems (e.g. micelles and 
liposomes), carbon nanotubes, and inorganic nanomaterials (e.g. nanodiamonds, gold and 
mesoporous silica nanoparticles) (Figure 1)(2, 14).  
DDS based on polymer are from utmost importance. For their preparation, the 
polymers can be from natural or synthetic origin and degradable or nondegradable. Natural 
polymers are polysaccharides, such as alginate(15, 16), chitosan(7), gelatin(15), cellulose(7), 
hyaluronic acid(17), amongst others(18). These natural polymers are abundant in nature, from 
renewable sources, with low cost, nontoxic, and present a high content of functional groups 
(such as hydroxyl, amino and carboxylic acid groups) that can be used in reactions for further 
bioconjugation (for example, with the purpose of cell targeting)(3, 18, 19). Synthetic polymers are 
those that are produced by polymerization, such as dendrimers(9), polyglycolic acid (PGA)(7), 
polyethylene glycol (PEG)(9, 13, 17), and poly(lactic-co-glycolic acid) (PLGA)(7, 20). Compared to 
natural polymers, synthetic ones have better controllable physicochemical properties. 
Degradable polymers contain labile bonds such as ester-, amide- and anhydride-bonds that 
are susceptible to hydrolysis or enzymatic degradation (surface degradation or bulk 
degradations)(21). These DDS based on polymers can physically encapsulate bioactive 
molecules within the polymeric network, including small drugs, proteins, and DNA/RNA. 
Alternatively, they can immobilize the bioactive molecules through chemical linkages. The 
incorporation of inorganic materials (such as quantum dots, and magnetic and gold 
nanoparticles) inside the polymer structure can also be done to obtain multifunctional systems 
(theranostic systems) that may have a therapeutic action beyond drug delivery(22). 
Actually, these polymer-based DDS can be found in a vast diversity of 
designs/architectures such as linear or branched polymers, dendrimers, polymersomes, and 
micelles, alone or in combination with other chemical entities/nanomaterials(9).  
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The design of a polymer-based nanocarrier is important for its chemical, interfacial, 
mechanical and biological functions(4). For example, the nanocarrier surface properties, such 
as hydrophilicity, lubricity, smoothness and surface energy, have a strong influence on its 
interaction with tissues and blood. Other important properties of a nanocarrier is its 
durability, permeability and degradability(4). 
 
 
 
 
Figure 1. Types of nanocarriers used for transporting drugs, nucleic acids or proteins (adapted from 
reference 2). 
 
 
1.3. Nanogels 
 
Nanogels are a special group of DDS based on hydrophilic polymers (it retains water 
in their structure). They are crosslinked hydrogel particles(3), within a size range between 10-9 
m (nanometer) and 10-6 m (micrometer)(9, 19). Nanogels are an important class of 
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nanomaterials that have excellent interior structures for drug encapsulation(7), and present all 
the properties of the bulk hydrogels, but at the nanoscale dimensions. So, nanogels are 
crosslinked polymeric particles with a high water content.  
The crosslinking in nanogels can be established by non-covalent physical associations, 
covalent chemical linkages, or combinations between them(23). The crosslinking methods that 
can be used to prepare nanogels include the use of ions, radiation, molecules with special 
functional groups, self-assembly, crystallization and crosslinking polymerization(24). Nanogels 
formed by physical crosslinking occur via non-covalent attractive forces, namely hydrophilic-
hydrophilic interactions, hydrophobic-hydrophobic interactions, ionic interactions and/or 
hydrogen bonding(23, 24). The properties of these nanogels are dependent on 
polymer/crosslinking agent composition and concentration, temperature and ionic strength 
of the medium. Nanogels formed by chemical crosslinking imply the reaction between 
crosslinking points along the backbone of the polymer chain(24) and usually makes use of 
crosslinking molecules. The properties of these nanogels (such as porosity and swelling) are 
strongly determined by the type of crosslinker and the extent of crosslinking reactions. The 
chemically crosslinked nanogels are, in principle, more stable than the physically 
crosslinked(23) but the use of crosslinkers may raise concerns related with toxicity(13).  
Because water is in their composition in large percentage, nanogels are usually 
biocompatible, and have suitable mechanical properties for DDS formulation(18, 22, 24). The 
physical properties that are mutual between the nanogels and the living tissues, are the 
consistency (soft and rubbery) and the low interfacial tension with water or biological fluids, 
which reduces the chances of a negative immune reaction (because protein adsorption and 
cell adhesion is minimized)(23). Furthermore, they show a huge loading capacity of water-
soluble compounds(13, 25). They are an excellent reservoir for drugs, oligonucleotides and 
imaging agents, which is due to the porosity inside the crosslinked network that also protects 
their cargo from possible environmental degradation(24, 25). Nanogels can have multifunctional 
properties that are dependent on  their crosslinking density, chemical functional groups, and 
surface-active and stimuli-responsive constituents(24). In fact, among other applications, 
nanogels have been used for drug delivery, but can also be applied in other fields such as 
sensing, diagnostics and bioengineering(26).  
These nanocarriers present several advantages such as a three-dimensional (3D) 
tunable size and physical structure, a large surface area for multivalent bioconjugation, a 
network for the incorporation of biomolecules and biodegradability for a sustained drug 
release(3, 18, 22, 23). In addition, nanogels also present flexibility and versatility, prolonged blood 
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circulation time and the option of being actively or passively targeted for a specific location, 
like tumor sites(27). 
Some important issues in nanogel development must be considered. For example, their 
stability in biological fluids which is essential to avoid aggregation(13, 24). It has been reported 
that nanogels with sizes around 100-200 nm have a higher cellular internalization efficiency, 
whereas small nanogels may result in a lower drug encapsulation and a fast drug release(13). 
On the other hand, negatively charged nanogels are better in terms of resistance to protein 
interaction (they have a longer blood circulation half-life), while positively charged nanogels 
are more susceptible to interact with the serum components (which may cause aggregation 
and minimize the blood circulation half-life)(28). Nevertheless, negatively charged nanogels 
may suffer repulsion by the negatively charged cell membrane, whereas the positively charged 
nanogels are more easily internalized by cells(28). 
The combination of specific properties like targetability and stimuli-responsiveness can 
be used to create the perfect nanogel(29). Indeed, nanogels have a characteristic which make 
them very interesting materials. They can be designed to be responsive to environmental 
stimuli like pH, temperature, ion strength or reduction agents (D,L-dithiothreitol (DTT), 
etc)(30), thus being an exceptional platform for biomedical applications. 
 
 
1.4. Nanogels based on Alginate 
 
Polysaccharides are known for their excellent physicochemical properties, 
biocompatibility and biodegradability(31). Alginate is a linear polysaccharide composed of β–
D-mannuronic acid and α–L-guluronic acid residues (Figure 2)(18, 27, 32-34). It is a biocompatible 
and biodegradable natural polymer, extracted from marine brown algae or produced by 
bacteria(16, 33-35). This polymer is considered safe by the U.S. Food and Drug Administration 
(FDA) for use in biomedical applications and is easily crosslinked in the presence of 
multivalent cations (calcium, barium, strontium, iron and aluminum) to form hydrogels 
which can be prepared at the nanoscale(32, 35-37). Ionic crosslinking with calcium ions is the 
most used method to prepare alginate hydrogels and consists in the combination of an 
aqueous alginate solution with a solution of divalent calcium cations(34). It is believed that the 
divalent cations bind to the guluronic blocks of the alginate chains, and form junctions in the 
polymer resulting in a gel structure(34). 
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Figure 2. Structure of the β–D-mannuronic acid (M block) and α–L-guluronic acid (G block) residues, 
and the alternating blocks in alginate (adapted from reference 34). 
 
 
As a consequence of the negative charge of its residues, alginate has a high degree of 
aqueous solubility, and a tendency for gelation under suitable conditions giving rise to 
nontoxic gels with a high porosity, low immunogenicity, and flexible to random geometries 
(27, 37). Alginate nanogels have many biomedical applications due to their exceptional 
properties, being able to deliver bioactive peptides and proteins, genes, and small drugs. 
Alginate macro or microgels can even encapsulate living cells, such as fibroblasts, human 
mesenchymal stem cells (hMSC), or others (16, 32). Beyond these applications, alginate can also 
be used in scaffolds for protein immobilization, and for neural, bone and cartilage tissue 
engineering(34, 37). However, ionic crosslinked alginate nanogels usually exhibit poor 
mechanical properties, uncontrolled degradation under the physiological conditions and a 
burst drug release because of cation exchange in the biological medium (e.g., exchange of 
calcium ions for sodium ions)(36). The use of an anionic surfactant, like dioctyl sodium 
sulfosuccinate (AOT), can overcome this limitation, through the formation of a bilayer 
around alginate nanogels, producing a sustained release of the drug(36). Another method to 
improve alginate based nanogel properties is through covalent crosslinking (e.g., by the 
reaction of the hydroxyl and carboxylic acid functional groups) with reactive groups present 
in crosslinking reagents, for example through carbodiimide chemistry(35).  
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1.5. Stimuli-responsive nanogels  
 
Stimuli-responsive nanogels are known to be sensitive/responsive when exposed to 
external signals, such as physical or chemical changes of the environment, are capable of 
changing their behavior. They are also named as “environment sensitive”, “smart” or 
“intelligent” polymers(27, 29, 31). These nanogels are able of controlled drug release in vivo when 
a specific stimuli is triggered in the target site(21). The response of nanogels to changes in the 
environment may be physical (e.g., variations in solubility, macromolecular structure, surface 
properties, swelling, and disassembly) or even a chemical reaction(29, 38). The external signals 
can be also classified in physical signals (such as changes in temperature, electric or magnetic 
fields, and mechanical stresses (ultrasound)), and chemical signals (such as changes in pH, 
ionic strength, and concentration of specific molecules like enzymes or reducing agents) 
(demonstrated in Figure 3)(10, 29, 31, 39). The release profile of the nanogels can be regulated by 
the stimuli-responsive units that are incorporated in the nanogel network(24). 
Dual responsive nanogels can also be prepared and, in fact, nanogels sensitive to pH 
and temperature variations have been widely studied(30, 39, 40). Nanogels that are simultaneously 
sensitive to pH and redox potential have been also reported(41). Indeed, although many 
different stimuli can be used to control the behavior of nanogels (in particular their drug 
release behavior), the pH, the temperature and the redox potential can be considered the most 
important.  
 
 
 
Figure 3. Behavior of nanogels with temperature, pH or other stimuli. e.g. the nanogel tend to swallow 
at lower temperature and shrink/collapse at higher temperature (adapted from reference 26). 
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pH-responsive nanogels 
 
It is well known that the extracellular environment of solid tumors may exhibit an 
acidic pH value (around 6.5)(3), whereas normal tissues present a pH around 7.4(31, 41). 
Furthermore, even more acidic pH values can be found in the human body, like in some 
intracellular compartments (endosomes and lysosomes presents a pH between 5.0 to 5.5)(3, 29). 
For this reason, efforts have been done to develop pH-responsive nanogels that are stable at 
physiological pH but reacts to pH changes towards lower values for a more efficient delivery 
of small drugs, nucleic acids or proteins in target sites(29, 31). pH-responsive polymers can be 
classified into two categories: polymers with ionizable groups, and polymers with degradable 
linkages(24, 31). In the first category, polymers having weak acid or base groups, such as 
carboxylic acids, phosphoric acids and amines, can present a change in the ionization state 
by varying the pH(31). The nanogels made from these polymers show an accelerated drug 
release that can be controlled through disassembly or dissolution(29, 31). These polymers also 
have an important characteristic which is the ability to dissociate and associate with protons 
in the aqueous environment, and therefore can be used as proton donors or acceptors(29, 40). 
The second category includes polymers that contain acid-degradable linkages(31). The 
nanogels made from these polymers may suffer induced cleavage in acidic conditions that 
results in an increase of the porosity and, possibly, further polymer dissolution(31).  
In response to changes in pH, nanogels based on polymers with ionizable groups go 
through a volume deformation(40). When the pH of the solution is higher than the pKa of the 
nanogel, e.g. poly(acrylic acid), the carboxylic groups are deprotonated carrying a negative 
charge, and resulting in the swelling of the nanogel. If these nanogels are loaded with 
hydrophilic drugs, then the swallow will result in a controlled drug release into the external 
medium. However, when the pH is lower than the pKa of the nanogel, the carboxylic groups 
are protonated shrinking the nanogel(40).  
 The applications of pH-responsive nanogels in drug delivery is very important and, in 
particular, in the delivery of anticancer therapeutics. 
 
 
Thermoresponsive nanogels 
  
Thermoresponsive (or temperature-responsive nanogels) are prepared from 
thermosensitive polymers. These polymers show a temperature-dependent phase transition in 
solution, passing through a critical temperature known as critical solution temperature (CST) 
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(29). For biomedical applications the transition temperature of the polymers should be between 
10-40ºC to be effective(17). If a polymer is water soluble below a defined temperature value 
and exists as a separated phase above that value, then it shows a lower critical solution 
temperature (LCST). If a polymer reveals the opposite behavior, then it shows an upper 
critical solution temperature (UCST)(29).  
The most studied thermoresponsive polymer is poly(N-isopropylacrylamide), 
PNIPAM. Since it was first reported in 1968, PNIPAM is extensively used in biomaterials, 
bioconjugates, actuators, and sensors(17). This polymer present a LCST about 32ºC because it 
goes through a reversible phase transition in water, from a swollen state (below 32ºC) to a 
collapsed state (above 32ºC)(29, 39, 40, 42, 43). By showing this behavior, it can be used to 
incorporate hydrophilic and hydrophobic molecules(17, 29, 30, 39, 40, 42, 44) that are released in 
response to temperature changes (PNIPAM hydrogels present a reversible swelling-
deswelling behavior)(13). At 32ºC, PNIPAM becomes insoluble in water, shrinking, due to a 
disruption of the hydrogen bonds formed between NIPAM units and water molecules(17, 30, 39). 
With these features, thermoresponsive nanogels with PNIPAM may have very interesting 
and promising applications in the biomedical field, like the treatment of certain cancers 
through hyperthermia(45). They can be loaded with an anticancer drug and, at the target 
location, by moderately increasing the temperature above the LCST, the nanogel can change 
of volume and the drug release can be accelerated(13, 29).  
 
 
Redox-sensitive nanogels 
 
The intracellular and the extracellular environment have a huge difference in terms of 
reduction potential, and that is being explored for triggering the intracellular delivery of 
drugs(41). For example, a reductive environment, such as the presence of an excess of 
glutathione (GSH), could be a powerful stimulus for drug delivery in the case of nanogels 
containing reducible bonds, such as disulfide bonds(28). Actually, it was reported that the 
cytosol of cancer cells has a concentration of GSH around 2-10 mM, which corresponds to 
1000 times more than that existent in the extracellular fluids, that presents a concentration 
between 2-20 µM(3, 11, 41, 46, 47). So, the presence of GSH in the cytosol can promote the cleavage 
of disulfide bonds existent in nanogels and help the release of the encapsulated drugs when 
using DDS(11, 28). On the other side, because of the low GSH concentration, the disulfide 
linkages should be stable in the circulation in normal physiological conditions(41). It was 
reported that endolysosomes contain a high concentration of the reducing enzyme γ-
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interferon-inducible lysosomal thiol reductase (GILT) and also of cysteine, both possibly 
contributing for a strong reducible environment(48). 
 
 
1.6. General objectives of the thesis 
 
The main goal of this thesis was to develop alginate (AG)-based nanogels for 
anticancer drug delivery with cell-responsiveness and/or sustained drug delivery behavior. 
The anticancer drug used in this study was Doxorubicin (Dox), a model drug extensively used 
to treat several types of cancers.  
 
In more detail: 
 
a) The first objective (Chapter II) was to prepare biocompatible redox-responsive 
nanogels based on disulfide-linked AG for intracellular delivery of Dox. The 
reducible nanogels were obtained through in situ crosslinking of AG by cystamine 
(Cys) via a miniemulsion method. The nanogels were characterized by Fourier 
transformed infrared spectroscopy (FTIR), dynamic light scattering (DLS), zeta 
potential measurements and scanning electron microscopy (SEM). Dox was 
loaded into the nanogels by simply mixing in aqueous solution, and the in vitro 
drug release was studied under normal and reductive conditions by UV-Vis 
spectroscopy. The antitumor activity was quantitatively and qualitatively studied 
against CAL-72 cells (an osteosarcoma cell line) using a cell metabolic activity 
assay and fluorescence microscopy, respectively.  
 
 
b) The second goal (Chapter III) was to develop AG nanogels with dual crosslinking 
for improved sustained drug delivery. The nanogels were prepared through an 
emulsion method using calcium ions and cationic poly(amidoamine) (PAMAM) 
dendrimers of generation 5 (G5) as crosslinkers. Furthermore PAMAM 
dendrimers were conjugated with fluorescein isothiocyanate (FI), a fluorescent 
marker, for following the path of nanogels once inside cells. The characterization 
techniques involved nuclear magnetic resonance (NMR), dynamic light scattering 
(DLS), zeta potential measurements and scanning electron microscopy (SEM). 
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The in vitro drug release was studied by UV-Vis spectroscopy and the biological 
assays (antitumor activity of the Dox loaded nanogels and their tracking inside 
cells) were performed using CAL-72 cells (an osteosarcoma cell line) and NIH 3T3 
fibroblasts (a non-carcinogenic cell line, used as a model of normal cells). Also in 
this case, quantitatively and qualitatively results were obtained through a cell 
metabolic activity assay and fluorescence microscopy, respectively.  
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Abstract 
 
Although doxorubicin (Dox) has been widely used in the treatment of different types 
of cancer, its insufficient cellular uptake and intracellular release is still a limitation. Herein, 
we report an easy process for the preparation of redox-sensitive nanogels which were shown 
to be highly efficient in the intracellular delivery of Dox. The nanogels (AG/Cys) were 
obtained through in situ crosslinking of alginate (AG) using cystamine (Cys) as a crosslinker 
via a miniemulsion method. Dox was loaded into the AG/Cys nanogels by simply mixing it 
in aqueous solution with the nanogels, that is, by the establishment of electrostatic 
interactions between the anionic AG and the cationic Dox. The results demonstrated that the 
AG/Cys nanogels are cytocompatible, have a high drug encapsulation efficiency 
(95.2±4.7%), show an in vitro accelerated release of Dox in conditions that mimic the 
intracellular reductive conditions, and can quickly be taken up by CAL-72 cells (an 
osteosarcoma cell line), resulting in higher Dox intracellular accumulation, and a remarkable 
cell death extension when compared with free Dox. The developed nanogels can be used as 
a tool to overcome the problem of Dox resistance in anticancer treatments, and possibly be 
used for the delivery of other cationic drugs in applications beyond cancer. 
 
 
 
 
 
 
 
 
 
Keywords: Doxorubicin; alginate; redox-sensitive nanogels; intracellular drug delivery 
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Introduction 
 
Cancer is one of the most serious diseases around the world. Doxorubicin (Dox), one 
of the smallest anticancer drugs, has been widely used for chemotherapy of several kinds of 
cancers of different organs, including bone(1), liver(2, 3) or breast(4). Dox is a member of the 
anthracycline family of anticancer drugs, and its use for cancer treatment can lead to a 
sequence of complications, such as tumor resistance, cellular toxicity and particularly 
cardiotoxicity(5). In the other hand, Dox presents antitumor activity since it intercalates in the 
DNA double helix and, as a consequence, inhibits DNA replication and the biosynthesis of 
macromolecules(5, 6).  
However, Dox is a weak base with a pKa of 8.30 and tends to undergo ion trapping in 
acidic conditions of the extracellular microenvironment of solid tumors (pH of 6.5 to 6.9) and 
in the internal milieu of endolysosomes (pH of 5.0 to 5.5)(6, 7). The ion trapping phenomenon 
is caused by the acidic regions of solid tumors creating a physiological barrier for the cellular 
uptake of weak bases, that are seized by acidic compartments, leading to drug resistance(7, 8). 
This occurs when there is a big difference between the permeabilization of ionized and 
nonionized species of a drug(7). 
Weak base drugs, such as Dox, ionize in solution, and an equilibrium is established 
between the protonated species with the uncharged, unprotonated form of the drug(8). While 
uncharged Dox can freely permeate membranes, the protonated Dox has a lower membrane 
permeability becoming trapped inside acidic compartments. Furthermore, Dox has been 
reported to have multidrug resistance(9, 10), possibly because of the p-glycoprotein, also known 
as the multidrug resistance protein, that is responsible for pumping unfamiliar molecules out 
of the cell. Therefore, free Dox can likely be pumped out of the cells by p-glycoprotein which 
shows enhanced activity in acid environments(9). Both these situations limit the therapeutic 
bioactivity of free Dox. So, to keep its desirable therapeutic efficacy, a large dosage or an 
increased number of injections may be needed which can lead to adverse side effects in normal 
tissues, especially in the heart and  kidneys, causing heart failure and cardiomyopathy among 
others malignancies and thus limiting its clinical applications(10-13). Due to these adverse 
effects, it is extremely important to develop biocompatible platforms for effective Dox 
delivery into the cytoplasm and/or the cell nucleus. 
Encapsulating anticancer drugs into nanocarriers can be the answer. The 
encapsulation of drugs may reduce or avoid the toxicity associated to the free drug, sustain 
the drug release, enhance drug solubility and allow targetability to cancer cells and/or tumors 
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site via the Enhanced Permeation and Retention (EPR) effect(14-17). Furthermore, the 
encapsulation of Dox inside nanocarriers can also protect it from recognition by the p-
glycoprotein, resulting in an improved intracellular accumulation and Dox resistance 
reduction(18). Cell-responsive nanocarriers, which are sensitive to intracellular 
microenvironmental stimuli, such as temperature(19), pH(20) and reduction potential(21), can be 
used as mean of  controlling the drug release. After arrival in tumor tissues, these smart 
nanocarriers can be endocytosed by cells and release the loaded drug triggered by intracellular 
stimuli, consequently exerting maximal antitumor activity and minimal side effects to the 
body(22).  
It is reported that the glutathione (GSH) concentration in the cytoplasm (about 2-10 
mM) is about 1000 times higher than that in the extracellular environment (about 2-20 μM)(23). 
Additionally, the GSH concentration in tumor cells is several times higher than in normal 
cells(24). Protection and detoxification are some of the functions of GSH, which can be one of 
the reasons that explains  the decrease in cytotoxicity of many chemotherapeutic agents(24).  It 
was also reported that endolysosomes contain a high content of a specific reducing enzyme 
γ-interferon-inducible lysosomal thiol reductase (GILT) and also of cysteine(23). As such, 
disulfide bonds present in the nanocarriers will be easily degraded in this reducing 
environment, while remain more stable in the extracellular space with lower -SH 
concentration. The development of reducible nanosystems (containing -SH-cleavable 
disulfide bonds) for efficient delivery of antitumor drugs is a challenge for researchers(23-25). 
Compared to other nanocarriers, such as liposomes(26, 27), micelles(28), dendrimers(29, 30) 
hydroxyapatite nanoparticles(31), and nanotubes(32, 33), nanogels show good biocompatibility, 
high aqueous dispersability and stability, well-defined structure and multifunctional 
possibilities(34, 35). As a natural and nontoxic biodegradable polymer, alginate (AG) has been 
widely investigated for therapeutic applications(36). AG is an anionic polymer that can form 
gels and encapsulate cationic molecules very effectively due to their high binding ability 
(through electrostatic interactions) and thus increased drug loading capacity(37). Recently, 
calcium-crosslinked AG nanogels (Ca2+-AG) have been fabricated and used for delivery of 
Dox with improved antitumor activity(38, 39). However, pure Ca2+-crosslinked AG nanogels 
have uncontrollable stability and often give a burst drug release, probably caused by the rapid 
exchange of Ca2+ with other cations present in phosphate buffered saline (PBS) solution(38, 40). 
Additionally, only limited amount of Dox is released from Ca2+-AG nanogels, which hampers 
the Dox antitumor efficacy(39). Chang et al. synthesized oxidized sodium alginate and then 
thiolated it to get thiolated alginate (AG-SH), which then assembled into reducible AG 
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nanoparticles in water by oxidation of AG-SH in air (41). However, the synthesis process was 
very complicated, and the AG-SH was difficultly stored due to its sensitivity to oxygen in air. 
Also, aggregation was a problem during the disulfide crosslinking process. 
In this work, a simple approach was employed to develop biocompatible reduction-
responsive nanogels based on disulfide-linked alginate for efficient intracellular delivery of 
Dox. The reducible nanogels with controllable size were synthesized through in situ 
crosslinking of alginate by cystamine via a miniemulsion method. The nanogels were shown 
to have excellent biocompatibility. Dox was loaded into the nanogels by simply mixing in 
aqueous solution, and the in vitro drug release was accelerated in intracellular reductive 
conditions. These Dox-loaded nanogels showed improved antitumor activity towards CAL-
72 cells (an osteosarcoma cell line), compared to free Dox.  This study is expected to be helpful 
for the design of more effective and safer nanogel-based drug carrier systems which may find 
applications in a wide range of fields. 
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Materials and Methods 
 
Materials 
Alginate acid sodium salt (from brown Algae, Mw from 12 to 58 kD, cell culture 
tested) (AG) was purchased from Sigma, USA. Cystamine dihydrochloride (Cys) was bought 
from Fluka. 1-Ethyl-3-(3-Dimethylamino propyl) carbodiiamide hydrochloride (EDC) was 
bought from J&K Chemical Ltd. Dioctyl sodium sulfosuccinate (AOT) was obtained from 
Sigma-Aldrich. Dichloromethane (DCM) HPLC grade was purchased from Fisher. Polyvinyl 
Alcohol (PVA, Mw 72000 Da) was bought from Merck, Germany. Doxorubicin 
hydrochloride (Dox) was obtained from Aldrich and used as received. D,L-Dithiothreitol 
(DTT) was purchased from Sigma Aldrich. CAL-72 cells were purchased DSMZ, Germany. 
4’, 6-Diamidino-2-phenyindole dilactate (DAPI) was bought from Sigma, USA. 
Glutaraldehyde was obtained from Merck, Germany. Dulbecco’s phosphate buffer saline 
(PBS) (without Ca2+ and Mg2+) was bought from Invitrogen Corporation, USA. All the other 
reagents were purchased from Sigma, unless otherwise stated. 
 
 
Preparation and Characterization of the AG/Cys and AG/Cys-Dox Nanogels 
AG nanoparticles were prepared by adapting a published double emulsion method(38, 
39). A total of 2 g of 1 wt% AG aqueous solution was dropped into 0.25 mL of ultrapure (UP) 
water with 5.5 mg EDC, followed by stirring at 400 rpm for 3 h at room temperature. The 
mixture was dropped into 4 mL of 2.5 wt% AOT solution in DCM under stirring at 1000 
rpm. The mixture was stirred under 400 rpm for 5 min, and then was dropped into 30 g of 2 
wt% PVA aqueous solution, followed by stirring at 400 rpm for 10 min. 50 mg of Cys in 1 
mL UP water was dropped into the above solution, and then stayed overnight under stirring 
at 400 rpm for DCM evaporation. The obtained mixture was centrifuged (15000 rpm for 5 
min) and washed with distilled water (25 mL x 3 times). The precipitate was freeze-dried for 
3 days to get AG/Cys nanogels. 
The AG/Cys-Dox nanogels were prepared according to Figure 4 by dropping 2 mg 
Dox in 1 mL water into 5 mL UP water containing 50 mg of AG/Cys. The mixture was kept 
overnight under magnetic stirring, followed by centrifuge to remove free Dox. The 
supernatant was determined spectrophotometrically at 490 nm using an ultraviolet-visible 
(UV-Vis) spectrometer (Lambda 2, Perkin-Elmer) for indirect determination of the Dox 
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encapsulation efficiency (EE). The analysis was performed based on a Dox calibration curve. 
The least-squares approach was used to fit the data (the regression equation and the 
correlation coefficient at 490 nm were y = 12611x + 0.0299 and 0.9979, respectively). The 
experimental molar absorption coefficient for Dox was 12611 M-1. The precipitate was 
lyophilized and kept at 4 °C for further study. 
The Fourier transform infrared (FTIR) spectra of AG and AG/Cys nanogels recorded 
on a Spectrometer (Spectrum Two, Perkin-Elmer) in a transmission mode ranging from 650 
to 4000 cm-1 under ambient conditions. 
The particle size and the zeta potential of the AG/Cys and AG/Cys-Dox nanogels 
were measured using a Zetasizer Nano ZS (Malvern Instruments) equipment. The nanogels 
were dispersed in PBS and sonicated for 15 min before measurements. 
The morphology of the AG/Cys and AG/Cys-Dox nanogels were examined by 
scanning electron microscopy (SEM, JSM-5600LV, JEOL Ltd., Japan) with an operating 
voltage of 15 kV. Before measurement, the samples were dispersed in UP water under 
sonication (SK1200H, 50 W) for 10 min. The aqueous suspensions of the samples were 
dropped onto an aluminum foil, air-dried, and Au-sputtered coated before analysis. 
 
 
Figure 4. Schematic illustration of the formation and drug release of Dox-loaded (AG/Cys-Dox) 
nanogels. 
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In vitro drug release studies 
In triplicate, 1 mg of AG/Cys-Dox nanogels was dispersed in 2 mL of PBS at 37 ºC 
under a pH value of 7.4, in the absence and presence of 5 mM DTT. At different time 
intervals, the solutions were centrifuged at 12000 rpm for 5 min. The supernatants were 
analyzed spectrophotometrically at 490 nm using an UV-Vis spectrometer for the Dox release 
analysis. The cumulative release (Cr) of Dox against time was obtained according to the 
equation: 
𝐶𝑟 = 100 ∗
𝐴𝑏𝑠t
𝐴𝑏𝑠tot
                              (1) 
 
Where Abst and Abstot are the cumulative amount of drug released at time t and total 
drug contained in the nanogels used for drug release, respectively. 
 
 
Cell Biological Evaluation 
CAL-72 cells (an osteosarcoma cell line) were cultured in Dulbecco’s Modified Eagle 
Medium (D-MEM) containing 10% (v/v) fetal bovine serum (FBS, Gibco) and 1% (v/v) of 
an antibiotic-antimycotic 100x solution (AA, Gibco, with penicillin, streptomycin, and 
amphotericin B). The medium was supplemented with 1% (v/v) of L-glutamine 100x solution 
(Gibco) and 1% (v/v) of insulin-transferin-selenium 100x solution (ITS, Gibco). The cells 
were grown at 37ºC, in a humidified atmosphere, in an atmosphere of 5% carbon dioxide. 
Afterwards, the cells were harvested at 70-80% confluence, using trypsin-EDTA solution for 
the enzymatic detachment of the cells from the plastic substrate. 
For the cytotoxicity experiments,  CAL-72 cells  were first plated in 24-well plate for 
24 h at a seeding density of 16 x 103 cells per well. After one day, free Dox and AG/Cys-Dox 
nanogels solutions (with equivalent Dox concentrations), prepared in PBS buffer, were added 
to the cell culture media and then incubated for 48 h at 37ºC before the resazurin reduction 
assay. Solutions of PBS and AG/Cys nanogels in PBS (containing equivalent mass 
concentrations to those used in AG/Cys-Dox nanogel solutions) were used as controls.  
The cell viability was quantified by the measurement of the metabolic activity of the 
cells in the culture through the resazurin reduction assay. Briefly, after the 48 h incubation 
time, the cell culture medium was replaced with fresh medium containing resazurin at a 
concentration of 0.1 mg/mL and kept at 37ºC for 3 h. Afterward, aliquots of the cell 
supernatant were transferred to 96-well opaque plates and the resofurin fluorescence (λex=530 
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nm, λem=590 nm) was measured using a microplate reader (model Victor
3 1420, Perkin-
Elmer). Statistical analysis was performed using the IBM SPSS Statistics 20 software (IBM 
Inc., Armonk). One-way ANOVA with Tukey Post Hoc test was used to assess the statistical 
difference between group means. 
For the cell uptake study, cells were plated 24 h before the incubation, to allow the 
attachment. In these experiments, solutions of free Dox and AG/Cys-Dox nanogels were 
used at the same Dox concentration (the final concentrations in the wells were 0.5 µM). Cells 
were then incubated with the test solutions at 37ºC for 2 and 4 h. Subsequently, the cultures 
were washed with sterilized PBS buffer, fixed with 3.7% glutaraldehyde, stained with DAPI 
for 30 min, and visualized using a fluorescence microscope (Nikon Eclipse TE 2000E). 
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Results and Discussion 
 
Preparation and Physical Characterization of AG/Cys-Dox Nanogels 
Initially, an aqueous solution of AG was reacted with EDC to activate the AG 
carboxylic groups. The mixture was emulsified in DCM using AOT as surfactant. The 
obtained mixture was re-emulsified in a PVA aqueous solution, followed by the addition of 
Cys to crosslink AG-emulsified drops. The reaction rested overnight to evaporate the organic 
DCM, and was then centrifuged and washed with water to remove the remaining surfactants 
and side products. The final precipitate was lyophilized to obtain the disulfide-cross-linked 
nanogels (AG/Cys), as is illustrated in Figure 4. 
The AG/Cys nanogels were prepared and loaded with Dox in aqueous solution. The 
strong electrostatic interactions between the nanogels and Dox were taken in advantage in 
the formation of the Dox-loaded nanogels. The addition of Dox only in the second step of the 
production process was done to avoid the possible nondegradable chemical bond formation 
between the EDC-activated carboxylic acid groups on AG and the amino group of Dox (this 
would limit the Dox release efficiency and lower its bioactivity). Having this in mind, the 
procedure followed is different from the nanogels by ionic crosslinking that is the case where 
the drug is added to the initial AG solution(38, 39). 
 
 
Figure 5. FTIR spectra of pure AG and AG/Cys nanogels (a); (b) is an enlarged view of the spectra 
in the range of 1300 to 1900 cm-1. 
 
The chemical structure of AG and AG/Cys was further characterized by Fourier 
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cm-1 (the hydroxyl stretching vibration of the polysaccharide), and large absorption bands at 
1603 and 1416 cm-1 (asymmetric and symmetric stretching peaks of the carboxylate salt 
groups)(42). After the crosslinking reaction of AG with Cys, the intensity of the peaks at 1603 
and 1416 cm-1 was greatly reduced, and the peaks shifted to 1637 cm-1 (C=O stretching (amide 
I)) and 1555 cm−1 (NH in-plane bending (amide II))(43-45), indicating the formation of amide 
bonds between AG and Cys. The new peak at 1734 cm−1 of AG/Cys might be associated with 
the ester linkage (C=O stretching) of the surfactant, AOT, which can still remain in the 
nanogels(46).  
Dox is widely employed in the treatment of different types of tumors, as this molecule 
can bind DNA and block the synthesis of bioactive macromolecules(5). To better understand 
the potential applications of the obtained nanogels for drug delivery, Dox was selected as a 
model drug and used in the study of their loading and release properties. Dox-loaded AG/Cys 
nanogels (AG/Cys-Dox) were obtained via electrostatic interaction by simply mixing 
aqueous solutions of cationic Dox and of anionic AG/Cys nanogels. Subsequently, free Dox 
was removed by centrifugation, and the supernatant was analyzed with UV−visible 
spectrometer at 490 nm wavelength to determine the amount of unencapsulated Dox. As 
shown in Table 1, the AG/Cys nanogels presented high Dox encapsulation efficiency (95.2 
± 4.7%) and high loading capacity (3.7 ± 0.2%), revealing the successful loading of the drug 
and electrostatic binding to AG. Thereby, nanogels with a disulfide-cross-linked three-
dimensional structure were prepared and can effectively serve as a drug reservoir for cationic 
Dox. 
 
Table 1. Characterization of Dox-loaded AG/Cys Nanogels1 
 
Sample Size, nmb Zeta Potential, mV EE, %c LC, %d 
AG/Cys 207 + 47 -62 + 11 --- --- 
AG/Cys-Dox 318 + 62 -39 + 11 95.2 + 4.7 3.7 + 0.2 
 
 
                                                          
1The results are expressed as the mean+standard deviation (n = 3). bSize and zeta potential were measured in 
PBS at pH 7.4. cEncapsulation efficiency = 100 x Wt/W0, W0 and Wt are the total Dox weight used for 
encapsulation and the weight of encapsulated Dox, respectively. dLoading Capacity = 100 x Wt/W , Wt and W 
are the weight of encapsulated Dox and the weight of Dox-loaded nanogels, respectively. 
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Table 1 shows the hydrodynamic diameter (size) of the nanogels analyzed by dynamic 
light scattering (DLS) and the correspondent zeta potentials. The zeta potential appeared to 
display an increase from −42 ± 11 mV (AG/Cys) to −39 ± 11 mV (AG/Cys-Dox) in PBS (pH 
7.4) after the Dox encapsulation. Because of their hydrophilicity and negatively charged 
surface, the nanogels are expected to be very stable in physiological conditions. The size of 
AG/Cys was 207 ± 47 nm, which indicated that the nanogels were well dispersed in 
physiological buffer, while AG/Cys-Dox had a bigger size (318 ± 62 nm) than AG/Cys. The 
increase of size in the AG/Cys-Dox together with its likely increase in zeta potential indicates 
that Dox was successfully loaded into AG/Cys nanogels to form nanocomplexes. It is 
important to refer that the Dox-loaded nanogels can be lyophilized and redispersed very well 
in physiological buffer that can be confirmed by DLS analysis, which is an important factor 
for therapeutic formulations for long-term storage.  
The scanning electron microscopy (SEM) images for the two kinds of samples are 
shown in Figure 6. SEM micrographs indicate that AG/Cys are present as dispersed 
nanoparticles with a size ranging from 100 to 250 nm, which is in agreement with the results 
of DLS analysis. The loading of Dox into the AG/Cys does not appear to have affected the 
size of the nanogels (Figure 6b). It has to be mentioned that SEM micrographs reflect the dry 
state of materials. The higher hydrodynamic diameter of the AG/Cys-Dox than that of the 
Dox-free nanogels may be ascribed to the incorporation of the hydrophilic Dox, probably 
resulting in a more swollen state in PBS solution. 
 
 
 
Figure 6. Scanning electron microscope (SEM) images of the AG/Cys (a) and AG/Cys-Dox (b) 
nanogels. 
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In Vitro Drug Release of Dox-Loaded Nanogels 
The idea behind the design of these nanogels is that, after cellular uptake and in the 
presence of the intracellular reducible environment, the disulfide bonds can be cleaved to 
trigger the release of Dox into the cytosol and the nucleus (Figure 4). To check this hypothesis, 
the release behavior of Dox from the nanogels was studied in nonreducible and reducible 
environments, in PBS buffer, at pH 7.4. D,L-Dithiothreitol (DTT, 5 mM) was hereby applied 
as a reducing molecule to mimic the intracellular reducible environment and to examine the 
possible responsive release of the Dox loaded in the nanogels. As can be seen from Figure 7, 
after incubation in PBS for 30 min, a limited Dox amount (about 20.0 ± 3.2%) was released 
from the nanogels under normal physiological conditions (pH 7.4), whereas it was promptly 
enhanced (49.6 ± 3.3%) in the presence of 5 mM DTT. For both situations, the release process 
ended after 6 h, and final cumulative Dox releases of 23.1 ± 3.5% and 70.1 ± 1.6% were 
obtained, respectively, in the absence and in the presence of DTT. The drug release results 
clearly show that the nanogels have a reduction-triggered drug release behavior and 
destabilize in a medium mimicking the intracellular reductive environment. 
 
Figure 7. In vitro cumulative release of Dox from AG/Cys-Dox nanogels in the presence and absence 
of DTT (5 mM) in PBS buffer (pH 7.4) at 37ºC. The results are expressed as the mean + standard 
deviation (n = 3). 
 
 
Therefore, after being internalized by cells through endocytosis and after 
endosome/lysosome merging, the disulfide bonds present in the nanogels will be cleaved by 
the action of molecules with reductive properties, such as the specific reducing enzyme γ-
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interferon-inducible lysosomal thiol reductase (GILT) and cysteine, and undergo partial 
degradation. This accelerates the release of Dox from the nanogels which will reach the 
cytoplasm after endolysosomes rupture. Because the separation of Dox (positive) from the 
AG chains can be achieved through its substitution by protons (H+), an increase in the influx 
of protons to the endolysosomes can occur and facilitate their rupture through the known 
“proton-sponge effect”(47). Finally, reductive molecules existent in the cytoplasm, like 
glutathione (GSH), will further disassemble the redox-responsive nanogels, accelerate Dox 
release and allow the movement of Dox to the cell nucleus to kill cancer cells. 
 
 
In Vitro Cytotoxicity of Nanogels and Dox-Loaded Nanogels 
To evaluate the antitumor activity of Dox upon release from the nanogels, the in vitro 
cytotoxicity of Dox-loaded nanogels was tested using CAL-72 cells and the resazurin 
reduction assay. This assay is used as an indirect measure of cell viability because what is 
really being quantified is the cell metabolic activity (it is established a direct correlation 
between cell metabolic activity and the number of viable cells). Free Dox and AG/Cys 
nanogels were used as controls (as positive and negative controls, respectively). As shown in 
Figure 8, cell viability was dependent on Dox concentration. Both free Dox and AG/Cys-
Dox nanogels were able to inhibit the growth of CAL-72 cells at all tested Dox concentrations 
(compared with the PBS control). Free Dox alone exhibited the expected mild drug resistance 
with an IC50 above 2.0 μM, while the Dox-loaded nanogels displayed a higher inhibition 
efficacy towards CAL-72 cells (with obvious reduction in IC50 (0.9 μM)). Because the Dox-
free AG/Cys nanogels did not display any cytotoxicity, results indicate that the antitumor 
efficacy is specially related with the presence of Dox within the carriers. Actually, the cell 
viability of CAL-72 cells treated with AG/Cys nanogels for 48 h was above that obtained for 
the PBS control (100%), at all test concentrations (up to 30.4 μg/mL), which reveals that the 
nanogels even have a beneficial effect over the metabolic activity of the cells. The excellent 
cytocompatibility of the nanogels together with their efficacy as Dox carriers show that they 
have a high potential as platforms for the intracellular delivery of anticancer drugs. 
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Figure 8. Cytotoxicity of free Dox, AG/Cys-Dox nanogels (with equivalent Dox concentration), and 
AG/Cys nanogels (with equivalent weight concentration of the corresponding AG/Cys-Dox 
nanogels) was analyzed after 48 h of cell culture using CAL-72 cells. Results are reported as the mean 
+ standard deviation (n = 4). One-way ANOVA with Tukey’s Post Hoc test was used to assess the 
statistical difference between the group means (**p < 0.01, ***p < 0.001). 
 
 
In order to confirm the antitumor activity of the nanogels, the morphology of cells 
treated for 48 h with free Dox, AG/Cys, and AG/Cys-Dox nanogels were observed by optical 
microscopy (Figure 9). Cells in the PBS control and those treated with AG/Cys nanogels 
exhibit a fusiform shape and are adherent on the cell dish surface, indicating that the AG/Cys 
nanogels are quite cytocompatible. At a Dox concentration of 0.5 μM, samples treated with 
free Dox have a portion of rounded and non-adherent cells, showing a moderate level of 
cytotoxicity. As a comparison, there are a high amount of rounded and non-adherent cells, 
and less quantity of fusiform and attached healthy cells, when AG/Cys-Dox nanogels 
containing 0.5 μM Dox were used, suggesting a larger cytotoxicity. The cell morphological 
results are in agreement with the quantitative analysis made by the resazurin reduction assay, 
showing that AG/Cys-Dox nanogels display a more efficient antitumor activity.  
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Figure 9. Cell morphology (optical microscopy) of CAL-72 cells after 48 h in culture with (a) control, 
(b) AG/Cys, (c) free Dox (0.5 µM), and (d) AG/Cys-Dox nanogels with an equivalent amount of Dox 
(0.5 µM). 
 
 
Cellular Internalization of Doxorubicin 
The uptake of the drug carriers by cells is one of the key factors for the achievement of 
therapeutic efficacy(48). Since Dox is a fluorescent molecule (it emits red light), its cellular 
uptake can be easily followed by fluorescence microscopy. The red fluorescence of Dox could 
be observed inside CAL-72 cells after 2 h of incubation for both the experiments performed 
with free Dox and with Dox-loaded AG/Cys nanogels (Figure 10). After 2 and 4 h 
incubation, the red fluorescence of Dox was observed not only in the cytoplasm but also in 
the nucleus. The results further show that the fluorescence intensity was lower for the 
experiments done in the presence of free Dox, than for those done using Dox-loaded AG/Cys 
nanogels (Figure 10). 
 
 
 
a) b)
c) d)
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Figure 10. Bright field and fluorescence microscope images of CAL-72 cells after 2 and 4 h culture 
with free Dox (0.5 µM) and AG/Cys-Dox with an equivalent amount of Dox (0.5 µM). The cell 
nucleus (blue) is stained with DAPI; Dox emits a red fluorescence signal. 
 
 
After 48 h in culture, the existence of cell death associated with a high Dox uptake is 
clearly evident in the assays performed with the AG/Cys-Dox nanogels and for a Dox 
concentration of 1.5 μM (Figure 11). The improved intracellular delivery of Dox obtained 
using the nanogels, combined with the accelerated release of Dox in response to the reductive 
intracellular environment, and a facilitated disruption of the endolysomal vesicles through 
nanogels action, make the nanogels powerful systems to be used as carriers for positively 
charged anticancer drugs. 
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Figure 11. Bright field and fluorescence microscope images of CAL-72 cells after 48 h culture with 
free Dox (0.5 and 1.5 µM) and AG/Cys-Dox containing an equivalent Dox concentration (0.5 and 
1.5 µM). The cell nucleus (blue) is stained with DAPI; Dox emits a red fluorescence signal (The scale 
bar represents 100 µm). 
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Conclusions 
 
We developed an easy approach to prepare redox-responsive nanogels to encapsulate 
Dox. The formed AG/Cys nanogels presented a high drug loading capacity and displayed a 
redox-controlled drug release sensitivity, which is triggered by conditions mimicking the 
reducible intracellular environment. The nanogels displayed an excellent cytocompatibility 
and could be effectively endocytosed by CAL-72 cells with enhanced intracellular Dox 
accumulation. Also, we believe that the exchange of Dox by protons in the nanogels inside 
the endolysosomal compartments may help their rupture and the release of Dox into the 
cytoplasm. In summary, the use of the developed nanogels as vehicles for Dox delivery 
resulted in an improved in vitro anticancer efficacy which might make them promising 
nanomaterials for the efficient intracellular delivery of anticancer drugs with less side effects 
in vivo. 
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Abstract 
 
Although, in general, nanogels present a good biocompatibility and are able to mimic 
biological tissues, their instability and uncontrollable release properties still limit their 
biomedical applications. In this study, a simple approach was used to develop dual-
crosslinked dendrimer/alginate nanogels (AG/G5), using CaCl2 as crosslinker and amine-
terminated generation 5 dendrimer (G5) as a co-crosslinker, through an emulsion method. 
Via their strong electrostatic interactions with anionic AG, together with crosslinker Ca2+, G5 
dendrimers can be used to mediate the formation of more compact structural nanogels with 
smaller size (433±17 nm) than that  (873±116 nm) of the Ca2+-crosslinked AG nanogels  in 
the absence of G5. Under physiological (pH 7.4) and acidic (pH 5.5) conditions, the size of 
Ca2+-crosslinked AG nanogels gradually decrease probably because of their degradation, 
while dual-crosslinked AG/G5 nanogels maintain a relatively more stable structure. 
Furthermore, the AG/G5 nanogels effectively encapsulate the anticancer drug doxorubicin 
(Dox) with a loading capacity of 3 folds higher than that of AG nanogels. The AG/G5 
nanogels were able to release Dox in a sustained way, avoiding the burst release observed for 
AG nanogels. In vitro studies show that the AG/G5-Dox nanogels were effectively taken up 
by CAL-72 cells (a human osteosarcoma cell line) and maintain the anticancer cytotoxicity 
levels of free Dox. Interestingly, G5 labeled with a fluorescent marker can be integrated into 
the nanogels and be used to track them inside the cells by fluorescence microscopy. These 
findings demonstrate that AG/G5 nanogels may serve as a general platform for therapeutic 
delivery and/or cell imaging. 
 
 
 
 
 
 
Keywords: Fluorescent nanogels; alginate; dendrimer; bioimaging; drug delivery 
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Introduction 
 
The clinical outcomes of many anticancer drugs, like doxorubicin (Dox), are still not 
acceptable because of the phenomenon of drug resistance(1). To achieve a desirable therapeutic 
efficacy, a large dosage or increased number of injections is often used, which may lead to 
adverse side effects on normal tissues(2, 3). However, the use of an appropriate drug nanocarrier 
can be an adequate tool to overcome this problem(4). Furthermore, the integration of imaging 
agents with chemotherapeutics into nanocarriers for simultaneous intracellular tracking and 
therapy can provide an improved approach in the treatment and study of cancer(5). In fact, 
fluorescent molecules can be used to locate materials inside cells and, for that, organic 
fluorophores and fluorescent proteins are the most widely used(6). Ideal fluorescent molecules 
present a few requests such as lasting high brightness, sufficient water dispersibility, good 
biocompatibility and facility of bioconjugation(6). Yet, to get nanocarriers with good 
biocompatibility, sufficient stability and long circulation time is still a challenge for in vivo 
medical applications(6-13). 
Nanogels are nanoscale three-dimensional hydrophilic polymer networks that swell in 
water(14). The nanogels have Hamaker constants similar to those of water and, so, the driving 
forces for their aggregation in biological fluids are low(13). Compared to other nanocarriers, 
nanogels have good biocompatibility, high aqueous dispersibility and a well-defined 
structure(15, 16). Due to these advantages, they are ideal systems to load biomarkers and/or 
drugs through appropriate physical or chemical conjugation(17). Moreover, nanogels have 
been proven to be internalized by cells more efficiently than conventional carriers such as 
liposomes which are less stable when compared with nanogels(18). It was also reported that, as 
drug carriers, nanogels can significantly improve the bioavailability and in vivo safety of 
drugs(19). 
As a kind of natural polymer, alginate (AG), a polysaccharide found in nature, is 
considered to be safe by the U.S. Food and Drug Administration, and has been widely used 
in a variety of biomedical applications(20). An emulsion technique has been frequently used to 
prepare biodegradable AG nanogels for Dox delivery using CaCl2 as a crosslinker
(21-23). 
However, pure Ca2+-crosslinked AG nanogels are not stable which is probably caused by the 
rapid exchange of Ca2+ with other cations present in the phosphate buffer saline (PBS) 
solution(22, 24). Such instability may result in a burst drug release profile, and thus cause reduced 
therapeutic efficacy and higher side effects to normal organs in the human body(21). 
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Poly(amidoamine) (PAMAM) dendrimers are macromolecules that have a 
hydrophobic core and a hydrophilic periphery and can act as effective nanocarriers for 
delivery of various drugs(25-28). These dendrimers can be functionalized with other molecules, 
including targeting ligands, imaging dyes and drugs, making them an excellent platform for 
specific targeting, gene transfection, imaging and disease treatment(28, 29). However, PAMAM 
dendrimers can result in high cytotoxicity mainly due to the damage caused by their high 
positively charged surface on the negatively charged cell membrane(30). Considering their 
strong electrostatic interactions with anionic AG, it is hypothesized that cationic amine-
terminated PAMAM dendrimers might be used, together with CaCl2, to develop AG 
nanogels with more controllable properties. On one hand, the dendrimers with a highly 
cationic charged surface are expected to enhance the stability of Ca2+-crosslinked AG 
nanogels through their strong electrostatic interactions(6). On the other hand, the shielding of 
AG on the surface of the dendrimers may improve the biocompatibility of the dendrimers. In 
addition, the use of multivalent dendrimers may endow AG nanogels with 
multifunctionality(8). 
In the present study, a new type of nanogels was developed by incorporating 
generation 5 amine-terminated PAMAM dendrimers (G5) and Dox into AG nanogels by 
using an emulsion method, where both CaCl2 and dendrimers acted as crosslinkers (). The 
stability, drug release behavior and anticancer cytotoxicity of the formed nanogels were 
investigated. Our results indicate that the dendrimers can be used to mediate the nanogels 
formation with better stability and drug release sustainability than the simple Ca2+-crosslinked 
AG nanogels. The Dox-loaded AG/G5 nanogels kept the anticancer bioactivity of Dox 
uncompromised. Furthermore, the amine-terminated G5 was further conjugated with 
fluorescein isothiocyanate (FI) to form a macromolecular imaging agent (G5-FI) that, once 
incorporated in the nanogels, allowed their visualization inside cells.  
 
 
Figure 12. Schematic overview of the nanogels conjugated with FI, with Dox encapsulation and the 
dual-crosslink.   
b) Emulsion
c) Dual Crosslinking
a) AG/DoxFI Conjugation
G5 AG/G5-FI-Dox nanogelsG5-FI
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Materials and Methods 
 
Materials 
Ethylenediamine core amine-terminated G5 PAMAM dendrimers (G5) with a 
polydispersity index less than 1.08 were purchased from Dendritech (Midland, MI), USA. 
Fluorescein Isothiocyanate (FI) was obtained from Sigma, USA. Alginate acid sodium salt 
(AG) (from brown Algae, Mw from 12 to 58 kDa, cell culture tested) was bought from Sigma, 
USA. Doxorubicin hydrochloride (Dox) was obtained from Zibo Ocean International Trade 
Co, Ltd., China. Dioctyl sodium sulfosuccinate (AOT) was obtained from Sigma-Aldrich, 
USA. Polyvinyl alcohol (PVA, Mw 72 kDa) was purchased from Merck, Germany. 
Dulbecco’s phosphate buffer saline (PBS) solution (without Ca2+ and Mg2+) was purchased 
from Panreac, Spain. Regenerated cellulose dialysis membrane (molecular weight cutoff, 
MWCO 14 kDa) was acquired from Spectra/Por, USA. 4’,6-diamidino-2-phenyindole 
dilactate (DAPI) was bought from Sigma, USA. Glutaraldehyde was obtained from Sigma, 
USA. All other chemicals were obtained from Aldrich and used as received. 
 
 
Synthesis of FI-Functionalized Dendrimers (G5-FI) 
G5 was conjugated with FI moieties, as previously reported by our team(29). Briefly, a 
solution of FI (8.2 mg, 0.02106 mmol) in DMSO (5 mL) was dropped in a solution of G5 
(100 mg, 0.00347 mmol) in ultrapure water (20 mL) under 400 rpm stirring at room 
temperature. The reaction proceeded for 24 h. The solution was dialyzed against PBS buffer 
(3 times, 1 L) and water (3 times, 4 L) for 3 days through a 14 kDa MWCO membrane, and 
lyophilized to give the orange product G5-FI. The G5 conjugates were characterized by 1H 
NMR. The number of FI moieties conjugated onto each G5 dendrimer (6.1) was estimated 
using the integrals of the 1H NMR signals associated with the dendrimers and the FI 
moieties(29). 
 
 
Preparation and Physical Characterization of AG/G5-Dox Nanogels 
One gram of AG/G5-Dox (1/0.5/x wt%, x = 0 or 0.2) or AG/G5-FI (1/0.5 wt %) 
aqueous solution in the absence or presence of 0.1 mL of 1 M sodium hydroxide (NaOH) 
solution, respectively, was dropped into 2 mL of 2.5 wt % AOT solution in dichloromethane 
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(DCM) under stirring (400 rpm) at room temperature. The selected Dox concentration was 
based on the results obtained in one of our previous reports(4). The mixture was stirred under 
400 rpm for 5 min, and then was dropped into 15 g of 2 wt % PVA aqueous solution, followed 
by stirring at 400 rpm for 30 min. Afterwards, 5 mL of 60 wt % of calcium chloride (CaCl2) 
aqueous solution was dropped into the above solution, and then stayed overnight under 
stirring at 400 rpm for evaporation of DCM. The obtained mixture was centrifuged (12 000 
rpm for 5 min) and washed with distilled water (25 mL x 3 times). The precipitate was 
lyophilized for 3 days to get AG/G5, AG/G5-Dox and AG/G5-FI nanogels. The 
concentration of Dox was determined in the supernatants by spectrophotometry at 490 nm 
using an ultraviolet-visible (UV-Vis) spectrometer (Lambda 2, Perkin-Elmer) for indirect 
calculation of Dox encapsulation efficiency. The AG nanogels with or without Dox, in the 
absence of PAMAM dendrimers, were also prepared in a similar way as above, and named 
as AG and AG-Dox nanogels, respectively. 
The particle size and zeta potential of the AG-Dox and AG/G5-Dox nanogels were 
measured using a Zetasizer Nano ZS (Malvern Instruments) equipment. The nanogels were 
dispersed in PBS under sonication for 15 min before measurements. The morphology of the 
AG-Dox and AG/G5-Dox nanogels was examined by scanning electron microscopy (SEM, 
JSM-5600LV, JEOL Ltd., Japan) with an operating voltage of 10 kV. Before measurement, 
the samples were dispersed in ultrapure water under sonication for 10 min. The aqueous 
suspensions of the samples were dropped onto an aluminum foil, air-dried, an Au-sputtered 
coated before analysis. 
 
 
In vitro drug release studies 
In triplicate, 1 mg of Dox-loaded nanogels was dissolved in 2 mL PBS at the pH values 
of 7.4 and 5.5 and kept at 37 ºC. At each predetermined time interval, the solution was 
centrifuged at 12 000 rpm for 2 min at room temperature. The supernatant was taken out and 
Dox concentration was determined spectrophotometrically at 490 nm at different intervals 
using an ultraviolet-visible (UV-Vis) spectrometer.  
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The cumulative release (Cr) of Dox against time was obtained according to the 
equation: 
Cr = 100 * Abst/Abstot                                             (1) 
 
Where Abst and Abstot are the cumulative amount of drug released at time t and the total 
drug contained in the nanogels used for drug release, respectively. 
 
 
Biological Assays 
CAL-72 cells (a human osteosarcoma cell line) and NIH 3T3 fibroblasts (used as a 
model of normal cells) were cultured in Dulbecco’s Modified Eagle Medium (D-MEM) 
containing 10% (v/v) fetal bovine serum (FBS, Gibco) and 1% (v/v) of an antibiotic-
antimycotic 100x solution (AA, Gibco, with penicillin, streptomycin, and amphotericin B). 
For CAL-72 cells the medium was supplemented with 1% (v/v) of L-glutamine 100x solution 
(Gibco) and 1% (v/v) of insulin-transferin-selenium 100x solution (ITS, Gibco). Both cell 
lines were grown at 37 ºC at a humidified atmosphere with 5% carbon dioxide. Afterwards, 
the cells were harvested at 70-80% confluence, using trypsin-EDTA solution for the 
enzymatic detachment of the cells from the plastic substrate. 
For the cytotoxicity experiments, CAL-72 cells and NIH 3T3 fibroblasts were first 
plated in 48-well plates at a seeding density of 12 x 103 cells per well. After one day, free Dox, 
AG-Dox and AG/G5-Dox nanogel solutions (with equivalent Dox concentrations), prepared 
in PBS buffer, were added to the cell culture media and then incubated for 48 h, at 37 ºC, 
before the resazurin reduction assay. Solutions of PBS, G5, AG and AG/G5 nanogels in PBS 
buffer were used as controls. Solutions of G5-FI and AG/G5-FI nanogels with equivalent 
mass concentration were employed for the cytotoxicity and cell imaging study. 
The cell viability was quantified by the measurement of the metabolic activity of the 
cells in culture through the resazurin reduction assay(31, 32). Briefly, after the 48 h incubation 
time, the cell culture medium was replaced with fresh medium containing resazurin at a 
concentration of 0.1 mg/mL, and kept at 37 ºC for 3 h. Afterwards, aliquots of the cell 
supernatant were transferred to 96-well opaque plates and the resorufin fluorescence (λex=530 
nm, λem=590 nm) was measured using a microplate reader (model Victor3 1420, Perkin-
Elmer). Statistical analyses were performed using the IBM SPSS Statistics 20 software (IBM 
Inc., Armonk). One-way ANOVA with Tukey Post Hoc test was used to assess the statistical 
difference between group means. 
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For the cell uptake study, cells were plated for 24 h before the incubation with the test 
solutions, to allow cell attachment. In these experiments, solutions of free Dox, AG-Dox and 
AG/G5-Dox nanogels were used at the same Dox concentration (the final concentrations in 
the wells were 0.5 μM). Cells were then incubated with the test solutions at 37 ºC for 4 h. 
Subsequently, the cultures were washed with sterilized PBS buffer, fixed with 3.7% 
glutaraldehyde and stained with DAPI for 30 min, and visualized using a fluorescence 
microscope (Nikon Eclipse TE 2000E). 
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Results and Discussion 
 
Preparation and Physical Characterization of Dox-loaded Nanogels  
The nanogels preparation was done according to the emulsion method presented in 
Figure 13. This method allows the formation of monodispersed nanoparticles which can be 
tuned by the presence of surfactant(s)(4). Table 2 shows the size (measured by dynamic light 
scattering (DLS)) and the zeta potential of the nanogels measured in PBS buffer. The AG 
nanogels had a size of 873±116 nm and a zeta potential of -75.0±4.5 mV, while AG/G5 
nanogels had a size of 433±17 nm and a zeta potential of -49.8±1.2 mV. The decrease in the 
size and increase in the zeta potential in AG/G5 nanogels indicates that the cationic G5 
dendrimers have been successfully integrated into AG nanogels which may have a more 
compact structure due to the strong electrostatic interactions between the G5 and anionic AG. 
The size decrease, together with their negatively charged surface, may be beneficial to the 
improvement of the in vivo stability of the AG nanogels, through reducing the possibility of 
their phagocytosis (large particles with a diameter of 2-3 μm can be taken up by phagocytosis) 
and negatively charged protein adsorption in plasma(33). The higher zeta potentials of Dox-
loaded nanogels compared to those of Dox free nanogels suggest the effective loading of the 
cationic Dox drug(4). The incorporation of G5 into the AG nanogels increased three times 
their loading capacity (Table 2). 
 
Figure 13. Schematic illustration of the formation of nanogels through a double emulsion method. 
Usually, an aqueous solution of hydrophilic polymers (precursor) is emulsified in a surfactant organic 
solvent to form a water-in-oil (W/O) system. The mixture is then re-emulsified in an aqueous solution 
of a second surfactant to obtain a water-in-oil-in-water (W/O/W) system. The double-emulsified 
drops undergo physical and/or chemical crosslinking, followed by organic solvent removal and 
purification (e.g., centrifugation) to obtain nanogels. 
 
Double Emulsion Crosslinker
Purification
W/O system W/O/W system Crosslinked Nano-drops
Nanogels DispersionNanogels
Hydrophilic 
Polymer(s)/Drug 
Aqueous Solution
Surfactant in 
Organic Solvent
Second Surfactant 
Aqueous Solution
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Table 2. Characterization of Dox-free and Dox-loaded nanogels2. 
 
Sample Size, nma Zeta Potential, mV EE, %b LC, %c 
AG 873+116 -75.0+4.5 - - 
AG-Dox 840+108 -66.7+2.9 31.8+0.9 1.8+0.1 
AG/G5 433+17 -49.8+1.2 - - 
AG/G5-Dox 374+6 -39.9+1.9 72.5+0.2 5.6+0.2 
AG/G5-FI 462+17 -41.9+3.7 - - 
 
 
 
Figure 14. Scanning Electron Microscope (SEM) images of the AG-Dox (a) and AG/G5-Dox (b) 
nanogels. 
 
 
The Dox-loaded AG and AG/G5 nanogels were further examined by Scanning 
Electron Microscopy (SEM). As shown in Figure 14, it is evident that both nanogels are 
present as dispersed nanoparticles, with larger sizes than those measured by DLS, probably 
because of the extension of soft nanogels on the surface during their dry process for SEM 
analysis. Generally, AG/G5-Dox nanogels had a smaller size than those obtained for AG-
Dox nanogels, which is in agreement with the results of DLS analysis.  
                                                          
2 The results are expressed as the mean+standard deviation (n = 3). a Size and zeta potential were measured after 
2 h incubation in PBS at pH 7.4. b Encapsulation efficiency = 100*Wt/W0, W0 and Wt are the total Dox weight 
used for encapsulation and the weight of encapsulated Dox, respectively. c Loading capacity = 100*Wt/W, Wt 
and W are the weight of encapsulated Dox and the weight of Dox-loaded nanogels, respectively. 
 
a) b)
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Figure 15. Sizes of AG, AG-Dox, AG/G5 and AG/G5-Dox nanogels in PBS as a function of time 
at the pH values of 7.4 and 5.5. The results are expressed as the mean ± standard deviation (n = 3). 
 
 
It is known that the stability of the nanocarriers in the physiological environment is 
important for their in vivo applications(34). In order to evaluate the stability of the nanogels, 
their hydrodynamic sizes were analyzed in PBS solution at two different pH values (7.4 and 
5.5) (Figure 15). Under physiological conditions (pH 7.4), the sizes of AG nanogels before 
and after Dox loading gradually decreased with the increase of the incubation time (the 
experiments were done along 7 days), probably because of the degradation of the nanogels 
caused by the rapid exchange of Ca2+ with the cations in the PBS buffer(22, 24). Compared to 
the corresponding AG systems, AG/G5 nanogels in the absence or presence of Dox had less 
fluctuations in their size during the same period, indicating that the presence of G5 improved 
the nanogel stability, possibly through the co-crosslinking of AG macromolecules with G5 
and Ca2+. The Dox loading seems not to have a significant effect on the size behavior of both 
AG and AG/G5 nanogels under similar treatments. 
Generally, the sizes of the nanogels at pH 7.4 are larger than those of the corresponding 
ones at pH 5.5, suggesting that the nanogels presented a more condensed structure at pH 5.5. 
The pKa of AG is 3.49(35). PAMAM dendrimers have a pKa value of 9.2 for their primary 
amine groups, and a pKa of 6.7 for their tertiary amine groups(36). At pH 5.5, AG/G5 also had 
a more stable structure than AG nanogels, which may be reasonably attributed to the 
enhanced crosslinking density of the anionic AG in the presence of the cationic G5 
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dendrimers(37). As PAMAM dendrimers undergo higher degree of protonation at pH 5.5 than 
at pH 7.4, a denser crosslinking and a decreased size are expected at pH 5.5. Therefore, the 
G5 dendrimers enable the formation of a more compact complex with negatively charged AG 
through electrostatic interactions(36, 38). Interestingly, even though AG/G5-Dox appeared to 
have smaller sizes than those of AG/G5 under physiological conditions (pH 7.4), the previous 
exhibited larger sizes than those after at acidic conditions (pH 5.5), which may be caused by 
Dox protonation that induces the swelling of the nanogels(39). 
 
 
In vitro drug release of Dox-loaded nanogels 
For anticancer therapeutic applications, the encapsulated Dox should be able to be 
released into cancer cells to exert its biological activity. However, nanogels with loose and 
uncontrollable structure may result in a burst release due to the rapid escape of the drug from 
their interior(24). In Figure 16, it can be seen that the release kinetics of Dox from AG/G5-
Dox was investigated in vitro, in PBS solution, at pH values of 7.4 and 5.5, using AG-Dox as 
a control. At the physiological pH value, a burst release (56.7%) occurred in AG-Dox within 
1 h, while only 21.3% of Dox was released from AG/G5-Dox during the same period.  The 
burst release of AG-Dox may be ascribed to the fast disintegration of AG caused by the rapid 
exchange of Ca2+ with cations in the PBS solution(22, 24). The presence of G5 as a co-crosslinker 
for AG/G5-Dox resulted in a denser structure and better stability, thus reducing the burst 
release. It has to be mentioned that G5 dendrimers can also act as a drug carrier for Dox 
delivery, which may also limit the Dox release rate from the nanogels(8). After 2 h of 
incubation, Dox concentration rapidly decreased (from 56.7% at 2 h to 35.8% at day 12, 
probably due to the degradation of free Dox induced by hydrolysis in PBS solution(40). As an 
alternative, AG/G5-Dox nanogels kept a constant level of drug concentration until day 12, 
which may be attributed to their sustainability in drug release(41). 
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Figure 16. The cumulative release profile of Dox from AG-Dox and AG/G5-Dox nanogels in PBS 
buffer at the pH values of 7.4 and 5.5. An enlarged graph of the first 8 h (a), and during 12 days (b). 
The results are expressed as the mean ± standard deviation (n = 3). 
 
 
With a decrease of the pH value from 7.4 to 5.5, the Dox release rate and release 
efficiency of the AG-Dox were improved. Probably this happens because Dox diffusion rate 
increased due to its protonation under acidic conditions and thus higher hydrophilic 
character. Interestingly, the AG/G5-Dox maintained a sustained release in an acidic 
environment and kept a high level concentration of Dox during a long period of time (12 
days). That is, the presence of G5 endowed the nanogels with a sustainable release ability and 
good release efficiency at the pH 5.5 (near the pH of the endolysosomal compartments), 
which may be beneficial in terms of long-term anticancer activity. Inclusive, these results 
further confirm the role played by dendrimer crosslinking and indicate that the nanogels 
afford a sustained release of the drug over time. 
 
 
In vitro cytotoxicity and cellular internalization of Dox-loaded nanogels 
To test the biocompatibility of the AG/G5 and the antitumor activity of the AG/G5-
Dox, a cell viability assay was carried out using CAL-72 cells, based on the metabolic activity 
of cells in culture. As can be seen in Figure 17, G5 dendrimers were very toxic for CAL-72 
cells at all tested solutions. Comparatively, AG/G5 nanogels exhibited a good 
biocompatibility (even better than those of the corresponding AG nanogels at higher 
concentrations). It is known that cationic dendrimers can establish strong interactions with 
biological membranes, which causes high cytotoxicity by inducing membrane disruption via 
nanohole formation, membrane thinning and erosion(28, 42). Due to the existence of strong 
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electrostatic interactions between anionic AG and cationic G5, the anterior can act as a 
biocompatible coating that shields the cationic surface of G5. In fact, our results show that 
the zeta potential of AG/G5 nanogels is negative (-49.8±1.2mV, Table 2), indicating the 
presence of negative surface charges in AG/G5 nanogels(43, 44). This may be the main reason 
why AG can improve the biocompatibility of G5 dendrimers. 
 
 
Figure 17. Cytotoxicity of AG/G5-Dox nanogels after 48 h using CAL-72 cells (a) and NIH 3T3 cells 
(b). AG-Dox, AG/G5-Dox and free Dox had equivalent Dox concentrations. G5, AG/G5 and 
AG/G5-Dox nanogels had equivalent weight concentrations. Results are reported as the mean ± 
standard deviation (n = 4). One-way ANOVA with Tukey’s Post Hoc test was used to assess the 
statistical difference between the group means (*p < 0.05, ***p < 0.001). 
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More importantly, Dox-loaded AG/G5 were able to inhibit the growth of CAL-72 
cells, with inhibition efficiency comparable to that of the free Dox. For example, at a Dox 
concentration of 2.78 μM, almost 40% of CAL-72 cells died after treatment with both free 
Dox and AG/G5-Dox samples. Under the same conditions, the Dox-free AG/G5 did not 
induce any cytotoxicity, showing cell viability (97%) similar to the untreated control cells. 
Therefore, the anticancer bioactivity is only caused by the loaded drug within the nanogels. 
It has to be noted that around 20% of released Dox during the cell culture time (48 h) produced 
a similar in vitro anticancer activity to that achieved by free Dox alone (100%). Although AG-
Dox had higher cytotoxicity to CAL-72 cells, it was even more toxic to NIH 3T3 cells. This 
means that, in vivo, the use of these materials may result in severe side effects in normal 
organs. As such, it is believed that the sustainability in Dox release of AG/G5-Dox nanogels, 
together with their small size (smaller than the size of AG-Dox nanogels), is important for in 
vivo therapeutic applications, specifically to maintain a long-term anticancer bioactivity. 
 
 
 
Figure 18. Cell morphology of CAL-72 cells after 48 h in culture with (a) control, (b) AG/G5, (c) 
AG, and (d) free Dox (2.78 μM), and (e) AG/G5-Dox nanogels and (f) AG-Dox with an equivalent 
amount of Dox (2.78 μM). 
 
 
To further confirm the antitumor activity of the Dox-loaded nanogels, the morphology 
of cells after 48 h incubation with free Dox, AG nanogels and AG/G5 nanogels with and 
without Dox, were investigated by optical microscopy (Figure 18). Cells treated with PBS 
(control) and those treated with Dox-free AG and AG/G5 nanogels maintained a healthy 
a)
d)
b)
e)
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f)
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morphology (a fusiform shape and adherence on the cell dish surface). This indicates that 
both AG and AG/G5 nanogels are quite cytocompatible. At a Dox concentration of 2.78 
μM, fusiform (attached cells) and rounded (non-adherent cells or cells in a process of losing 
the adherence to the surface) cells existed in the samples treated with free Dox and AG/G5-
Dox, indicating that they had a similar cytotoxicity. However, at the same Dox 
concentration, more cells cultured with AG-Dox died, as it can be observed by the existence 
of less adherent cells and more cell debris. The cell morphology results are in line with the 
metabolic activity quantitative data, indicating that Dox within the AG/G5-Dox did not 
weaken the antitumoral activity of free Dox. 
 
 
 
 
Figure 19. Optical and fluorescence microscope images of CAL-72 cells after 4 h culture with free 
Dox (0.50 μM), AG/G5-Dox and AG-Dox nanogels with an equivalent amount of Dox (0.50 μM). 
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Figure 20. Enlarged optical and fluorescence microscope images of CAL-72 cells after 4 h culture with 
AG/G5-Dox nanogels with an amount of Dox (0.50 μM). The cell nucleus (blue) is stained with 
DAPI; Dox emits a red fluorescent signal (300x magnification). 
 
 
Taking advantage of its fluorescent nature, the extent of Dox internalization in CAL-
72 cells was evaluated by fluorescence microscopy, after their exposure to the drug, and AG-
Dox and AG/G5-Dox nanogels (Figure 19 and Figure 20). A red fluorescence signal was 
visualized in cell cytoplasm for all situations under study. Compared to the free Dox, cells 
cultured in the presence of the Dox-loaded nanogels displayed a stronger red fluorescence, 
indicating that the presence of nanogels accelerates the Dox uptake process. Considering the 
ability of AG/G5-Dox nanogels to sustain the drug release, we believe that they can act as 
Dox shuttles across the cell membrane and facilitate its intracellular release, resulting in a 
prolonged anticancer activity(45). 
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Figure 21. Optical and fluorescence microscopy images of CAL-72 cells after 48 h culture with (a-d) 
AG/G5-FI nanogels (50 μg/mL), (e-h) G5-FI (50 μg/mL). 
 
 
 
 
Figure 22. Enlarged optical and fluorescence microscopy images of CAL-72 cells after 48 h culture 
with AG/G5-FI nanogels (50 μg/mL). The cell nucleus (blue) is stained with DAPI; FI emits a green 
fluorescent signal (300x magnification). 
 
 
The efficient uptake of the nanogels by cells is also one of the key factors for 
achievement of therapeutic efficacy(46). The inclusion of a fluorescent probe into the nanogels 
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can provide valuable information concerning the path followed by the drug nanocarrier. 
Therefore, we synthesized a macromolecular bioimaging marker (G5-FI) by conjugating G5 
with a fluorescent molecule, fluorescein isothiocyanate (FI). G5 dendrimer was conjugated 
with FI, confirmed through NMR analysis (Figure 23). Then using a similar approach, G5-
FI was used, instead of G5, for fabrication of AG/G5-FI nanogels (462±17 nm). To check if 
the nanogels could be internalized and accumulated in cells for bioimaging, CAL-72 cells 
were incubated with the nanogels for 48 h, respectively. After treatment, cells were fixed and 
visualized by fluorescence microscopy. As can be seen in Figure 21 and Figure 22, both green 
(due to FI fluorescence emission) and blue (due to DAPI fluorescence emission) colors were 
observed in cell cultures after 48 h incubation, which indicated that the nanogels could be 
effectively taken up by cells, maybe through two popular mechanisms of both phagocytosis 
and diffusion via cell walls, in agreement with the previous report(47).  
 
 
 
 
Figure 23. 1H NMR spectrum of G5-FI in D2O. 
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Figure 24. Cytotoxicity of G5, G5-FI and AG/G5-FI nanogels after 48 h incubation with CAL-72 
cells. G5, G5-FI, and AG/G5-FI nanogels had equivalent weight concentrations. Results are reported 
as the mean ± standard deviation (n = 3). One-way ANOVA with Tukey’s Post Hoc test was used to 
assess the statistical difference between the group means (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
Most significantly, after 48 h of incubation the cells treated with AG/G5-FI did not 
change the cell morphology, suggesting that they have good biocompatibility. Contrarily, G5-
FI dendrimers were very toxic, inducing the death of almost all the cells. These results are in 
agreement with the quantitative data obtained in the corresponding cell viability assays shown 
in Figure 24. The properties above make us believe that the nanogels can act as a very 
interesting platform for therapeutic and bioimaging purposes. 
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Conclusions 
 
We report an elegant approach to construct stable AG/G5 nanogels using both CaCl2 
and PAMAM G5 dendrimers as crosslinkers through a double emulsion method. The AG-
based nanogels were shown to be stable and biocompatible. In these nanogels, the G5 
dendrimers, through their strong electrostatic interactions with anionic AG, are able to assist 
the formation of nanogels that are more compact than those prepared using only Ca2+ cations 
as a crosslinking agent. The presence of G5 can increase by 3 folds the loading capacity of the 
anticancer drug Dox in AG nanogels, and maintain an ability to sustain Dox release by 
avoiding its burst release occurring in AG nanogels. Furthermore, the Dox-loaded AG/G5 
nanogels can be effectively taken up by CAL-72 cells (a human osteosarcoma cell line) and 
intracellular deliver the drug to exert its anticancer cytotoxicity. In addition, G5 dendrimers 
marked with a fluorescent molecule can be incorporated into the nanogels and allow their 
tracking by fluorescence microscopy once inside cells. In conclusion, the nanogels exhibit a 
sustainable delivery of an anticancer drug as well as an intracellular imaging function through 
fluorescent detection. The presented results demonstrate that AG/G5 nanogels are expected 
to be a promising platform for therapeutic delivery and/or bioimaging applications. 
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Final Conclusions 
 
In summary, nanogels based on alginate can be an excellent platform for biomedical 
applications, namely for anticancer drug delivery. The results of the present work show that 
alginate, a natural polymer, can be used for the preparation of nanogels with exceptional 
properties in terms of biocompatibility and ability of loading drugs (such as doxorubicin). 
Furthermore, it is possible to produce alginate nanogels that respond to environmental 
stimuli, including pH variations, and redox conditions. Due to their stimuli-responsiveness, 
these nanocarriers can preferentially deliver the drugs in cell specific sites, making them 
extraordinary carriers for cancer or even other diseases. 
 
In Chapter II, a simple procedure for the preparation of redox-sensitive nanogels was 
reported. The synthesized nanogels (AG/Cys) were obtained via a miniemulsion method 
using cystamine as a crosslinker. Dox was loaded into the AG/Cys nanogels through 
electrostatic interactions between the anionic AG and the cationic Dox. The results 
demonstrated that the AG/Cys nanogels were cytocompatible, presented a high drug 
encapsulation efficiency, displayed an in vitro accelerated release of Dox in conditions 
mimicking the intracellular reductive environment, which could rapidly be internalized by 
CAL-72 cells, resulting in higher Dox intracellular accumulation, and a notable cell death 
when compared with free Dox. These nanogels may be an excellent platform to overcome the 
problem of Dox resistance in anticancer treatments and possibly be used for the delivery of 
other cationic drugs in applications beyond cancer. 
 
In Chapter III, an easy process was used to develop dual-crosslinked AG/G5 
nanogels, using calcium ions as crosslinkers and PAMAM G5 as co-crosslinkers, through an 
emulsion method. The dual-crosslinked AG/G5 nanogels showed a good cytocompatibility 
and were able of encapsulating the anticancer drug Dox. They displayed an improved drug 
release behavior when compared to the classical AG nanogels (those that used only calcium 
ions as crosslinkers). The biological studies showed that AG/G5 nanogels loaded with 
doxorubicin kept the anticancer cytotoxicity levels of free Dox and were successfully taken 
up by CAL-72 cells. The nanogels labeled with a fluorescent marker were shown to be useful 
for visualizing the nanogels inside cells by fluorescence microscopy. Thus, these resulting 
nanogels may serve as a general platform for therapeutic delivery and/or cell imaging.
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